Elsevier Science, Inc.

SHERPA: Unknown

People

  1. Horwitz
    Horwitz
  2. Sadelain
    Sadelain
  3. Slovin
    Slovin
  4. Arcila
    Arcila
  5. Levine
    Levine
  6. Abdel-Wahab
    Abdel-Wahab
  7. Castro-Malaspina
    Castro-Malaspina
  8. Giralt
    Giralt
  9. O'Reilly
    O'Reilly
  10. Stein
    Stein

Groups

  1. Hematologic Malignancies, Division of (282)
  2. Department of Medicine (281)
  3. Center for Hematologic Malignancies (209)
  4. GSK Faculty (86)
  5. Adult Leukemia (67)
  6. Sloan Kettering Institute Faculty (61)
  7. Solid Tumor Oncology Division (58)
  8. Lymphoma (56)
  9. Bone Marrow Transplant (50)
  10. Executive Committee, Center for Hematologic Malignancies (45)
Search Within
  1. "Hematologic Malignancies, Division of"
Formats
  1. Journal Article (155)
  2. Meeting Abstract (102)
  3. Review (14)
  4. Correspondence (4)
  5. Editorial (3)
  6. Guidelines (3)
  7. Research Letter (1)
Groups
  1. Hematologic Malignancies, Division of (282)
  2. Department of Medicine (281)
  3. Center for Hematologic Malignancies (209)
  4. GSK Faculty (86)
  5. Adult Leukemia (67)
  6. Sloan Kettering Institute Faculty (61)

More Groups

People
  1. Steven Horwitz (18)
  2. Michel Sadelain (16)
  3. Susan Slovin (14)
  4. Maria Arcila (13)
  5. Ross Levine (12)
  6. Anas Younes (11)

More People

Years
  1. 2025 (8)
  2. 2024 (16)
  3. 2023 (21)
  4. 2022 (15)
  5. 2021 (19)
  6. 2020 (26)

More Years

Publications
  1. Experimental Hematology (62)
  2. Lancet Oncology (47)
  3. The Lancet Haematology (32)
  4. Value in Health (22)
  5. Journal of Molecular Diagnostics (19)
  6. Lancet (14)

More Publications

Results (282)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Health-related quality of life (HRQoL) of large B-cell lymphoma (LBCL) and follicular lymphoma (FL) patients treated with axicabtagene ciloleucel (axi-Cel) in clinical trials and the real-world: A targeted literature review
    Meeting Abstract

    John, G.; Madhu, P.; Steve, K.; Sally, W.; Pardis, L.; Leah, Y.; Gunjan, S.
    Value in Health (2025)

    Fulltext@MSK | Save
  • Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: Primary results of a multicentre, single-arm, phase 2 study
    Journal Article

    Elimova, E.; Ajani, J.; Burris, H.; Denlinger, C. S.; Iqbal, S.; Kang, Y. K.; Kim, J. H.; Lee, K. W.; Lin, B.; Mehta, R.; more...
    Lancet Oncology (2025)

    Fulltext@MSK | Save
  • Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: A first-in-human, single-centre, phase 1 trial
    Journal Article

    Lou, E.; Choudhry, M. S.; Starr, T. K.; Folsom, T. D.; Bell, J.; Rathmann, B.; DeFeo, A. P.; Kim, J.; Slipek, N.; Jin, Z.; more...
    Lancet Oncology (2025)

    Fulltext@MSK | Save
  • Molecular heterogeneity and immune infiltration drive clinical outcomes in upper tract urothelial carcinoma
    Journal Article

    Kim, K.; Alam, S. M.; Kuo, F.; Chen, Z.; Yip, W.; Katims, A. B.; Chu, C.; Lenis, A. T.; Hu, W.; Gokturk Ozcan, G.; more...
    European Urology (2025)

    Fulltext@MSK | Save
  • Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): A single-arm, open-label, phase 1, dose-escalation study
    Journal Article

    Iyer, S. P.; Sica, R. A.; Ho, P. J.; Prica, A.; Zain, J.; Foss, F. M.; Hu, B.; Beitinjaneh, A.; Weng, W. K.; Kim, Y. H.; more...
    Lancet Oncology (2025)

    Fulltext@MSK | Save
  • Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): Results from a randomised, open-label, phase 3 trial
    Journal Article

    Mina, R.; Mylin, A. K.; Yokoyama, H.; Magen, H.; Alsdorf, W.; Minnema, M. C.; Shune, L.; Isufi, I.; Harrison, S. J.; Shah, U. A.; more...
    The Lancet Haematology (2025)

    Fulltext@MSK | Save
  • Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: A phase 1, first-in-human trial
    Journal Article

    Ghobadi, A.; Bachanova, V.; Patel, K.; Park, J. H.; Flinn, I.; Riedell, P. A.; Bachier, C.; Diefenbach, C. S.; Wong, C.; Bickers, C.; more...
    Lancet (2025)

    Fulltext@MSK | Save
  • Sample site impacts RNA biomarkers for renal cell carcinoma
    Journal Article

    Eismann, L.; Xie, A. X.; Tang, C.; Knezevic, A.; Ostrovnaya, I.; Kuo, F.; Ari Hakimi, A.; Reznik, E.; Kotecha, R. R.
    European Urology (2025)

    Fulltext@MSK | Save
  • OncoKB: Automated somatic variant classification for rapid clinical decision making
    Meeting Abstract

    Suehnholz, S.; Nissan, M.; Zhang, H.; Kundra, R.; Lu, C.; Dhaneshwar, A.; Fernandez, N.; Cavender, K.; Preiser, B.; Konecny, J.; more...
    Journal of Molecular Diagnostics (2024)

    Fulltext@MSK | Save
  • Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): A multicentre, open-label, single-arm, phase 2 study
    Journal Article

    Zinzani, P. L.; Izutsu, K.; Mehta-Shah, N.; Barta, S. K.; Ishitsuka, K.; CoĢrdoba, R.; Kusumoto, S.; Bachy, E.; Cwynarski, K.; Gritti, G.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save